Investor Alert

London Markets Open in:

Market Pulse Archives

Sept. 9, 2021, 7:17 a.m. EDT

Quest Diagnostics hikes financial estimates on Delta variant testing boost

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Quest Diagnostics Inc. (DGX)

or Cancel Already have a watchlist? Log In

By Steve Gelsi


Quest Diagnostics Inc. /zigman2/quotes/201001842/composite DGX -0.94% on Thursday raised its 2021 financial outlook on the heels of increased testing activity for Covid-19. Since the company issued its last projections on July 22, it's seen stronger-than-expected molecular testing volumes through the end of August. The surge of the Delta variant is expected to continue to boost testing volumes. The Secaucus, N.J., company now expects 2021 earnings of $12.54 to $13.24 per share, compared to its previous outlook of $11.48 to $12.18 per share, with adjusted earnings of $11.65 to $12.35 per share, up from its earlier view of $10.65 to $11.35 per share. Revenue for 2021 is expected to top $9.84 billion and total up to $10.09 billion. At last check, analysts surveyed by FactSet expect 2021 earnings of $11.41 a share and revenue of just under $9.8 billion. Quest Diagnostics stock rose 0.8% in pre-market trades.

$ 139.20
-1.32 -0.94%
Volume: 1.06M
May 18, 2022 4:03p
P/E Ratio
Dividend Yield
Market Cap
$16.49 billion
Rev. per Employee

Get news alerts on Quest Diagnostics Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.